Clinical Studies
Following are previously published articles that will help you better understand the use of Adequan®i.m. (POLSULFATED GLYCOSAMINOGLYCAN) in horses. We will update these offerings as new information becomes available. If you are interested in receiving the full article, email us.
Efficacy of Adequan®i.m. (polysulfated glycosaminoglycan) compared to Polyglycan® Intravenous
White G.W.
In a recent systemic comparison study of joint inflammation treatments, the efficacy of intramuscular Adequan®i.m. (polysulfated glycosaminoglycan) was found to be superior to a medical device known as Polyglycan®.
Traumatic arthritis and its treatment in the athletic horse
McIlwraith, CW
Traumatic arthritis is described and the available treatments are discussed.
The effect of drugs used in the treatment of osteoarthrosis on stromelysin (proteoglycanase) of equine synovial cell origin
May S.A., Hooke R.E., Lees P.
Confirms that PSGAG is the only equine antiarthritic drug to significantly inhibit the enzyme stromelysin at clinically relevant concentrations.
Polysulfated glycosaminoglycan accelerates net synthesis of collagen and glycosaminoglycan by arthritic equine cartilage tissues and chondrocytes
Glade M.J.
Demonstrates that PSGAG stimulates net collagen and glycosaminoglycan synthesis by normal and arthritic equine fetlock cartilage. Supports the chondroprotective role of PSGAG in equine DJD.
In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model
Burba D.J., Collier M.A., Default L.E., Hanson-Painton O., Thompson H.C., Holder C.L.
3H-PSGAG (500 mg) administered i.m to horses was distributed in the blood, synovial fluid and articular cartilage of the carpal joint. Hyaluronic acid concentrations in the synovial fluid increased after i.m administration of polysulfated glycosaminoglycan.
3H-PSGAG concentration in the synovial fluid of the equine antebrachiocarpal, metacorpophalangeal, cornopedal and tibiotarsal joints following a 500 mg injection
Haugland M.L., Collier M.A., DeBault L.E., Walls R.C., de Siqueira, L.F.G.
Study indicating that a single intramuscular injection of polysulfated glycosaminoglycan provides therapeutic levels of the drug in the equine antebrachiocarpal, metacarpophalangeal, tibiotarsal and cornopedal joints within 2 hours of injection.
The efficacy of orally administer sulfated glycosaminoglycan in chemically induced equine synovitis and degenerative joint disease
White G.W., Jones E.W., Hamm J., Sanders J.
An oral supplement containing sulfated glycosaminoglycan was evaluated in an equine degenerative joint disease model. No chondroprotective or antiinflammatory activity could be demonstrated when compared to untreated controls.
The current status of the clinical use of polysulfated glycosaminoglycan in the U.S.A.
Jones E.W., White G.W.
This paper provides a practical review of the clinical use of Adequan® in the United States and includes efficacy data as well as a discussion on the mode of action.
The efficacy of systematically administered anti-arthritics in an induced equine carpitis model
White G.W., Jones E.W., Stites T., Hamm J., Walls R., Sanders T.
Both Polysulfated Glycosaminoglycan (PSGAG) administered intramuscularly and sodium hyaluronate administered intravenously (HAIV) showed significant improvement from pretreatment baselines in a blinded induced carpitis model. PSGAG generated a quicker and significantly better response than HAIV in the trial.